Phase III, multicenter, randomized trial of 45 Gy versus 30 Gy thoracic radiation for extensive‐stage small cell lung cancer ( ES‐SCLC ): Study protocol
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15263 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Lei Deng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sci…. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Consolidative thoracic radiotherapy (cTRT) has previously shown benefit to patients with extensive stage small cell lung cancer (ES‐SCLC) who respond to chemotherapy. However, the optimum dose of cTRT is unknown. The purpose of this randomized trial is to compare the efficacy of 45 Gy in 15 fractions with 30 Gy in 10 fractions cTRT in ES‐SCLC.
Methods
This phase III, multicenter, randomized trial is designed to evaluate the safety and efficacy of different cTRT dose in ES‐SCLC. Eligible patients with pathologically confirmed ES‐SCLC who responded to 4–6 cycles of etoposide plus cisplatin (EP) or carboplatin (EC) chemotherapy were randomized 1:1 to receive either 30 Gy in 10 fractions (standard dose) or 45 Gy in 15 fractions (high dose) cTRT. The primary endpoint is 2‐year overall survival (OS). Secondary endpoints include 2‐year progression‐free survival (PFS), 2‐year local control (LC) and treatment related toxicity as measured by adverse events according to the Common Terminology Criteria for Adverse Events (version 4.0).
Discussion
The present study is the first randomized phase III trial designed to evaluate the efficacy of higher versus lower dose cTRT in ES‐SCLC, providing evidence for future clinical practice in prolonging survival of patients with ES‐SCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
- Department of Radiation Oncology, National Cancer Center/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Lei Deng, Gulidanna Shayan, Luhua Wang
Zitieren
APA
Deng, L., Shayan, G., Jiang, W., Bi, N., & Wang, L. (2024). Phase III, multicenter, randomized trial of 45 Gy versus 30 Gy thoracic radiation for extensive‐stage small cell lung cancer ( ES‐SCLC ): Study protocol. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15263
Vancouver
Deng L, Shayan G, Jiang W, Bi N, Wang L. Phase III, multicenter, randomized trial of 45 Gy versus 30 Gy thoracic radiation for extensive‐stage small cell lung cancer ( ES‐SCLC ): Study protocol. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15263
BibTeX
@article{Deng2024,
author = {Deng, Lei and Shayan, Gulidanna and Jiang, Wei and Bi, Nan and Wang, Luhua},
title = {Phase III, multicenter, randomized trial of 45 Gy versus 30 Gy thoracic radiation for extensive‐stage small cell lung cancer ( ES‐SCLC ): Study protocol},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15263}
}
EUVIMED